UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other juri ...

Exhibit 99.1 Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates BRANFORD, Conn. — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights ● Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or other jurisdict ...

Azitra (NYSEMKT:AZTR) stock is falling hard on Wednesday morning after the biopharmaceutical company’s shares underwent a massive rally yesterday.Azitra stock is down 75.2% as of Wednesday morning. That comes with some 6.3 million shares of the stock traded. For the record, the company’s daily average trading volume is about 1.3 million shares.Yesterday’s trading saw the tock close out normal hours up 206.8%. That came with more than 75 million shares of AZTR stock changing hands. Unfortunately for investor ...

Azitra (NYSEMKT:AZTR) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents.This covers the company’s filaggrin-secreting strain of Staphylococcus epidermidis. A patent was issued to it on July 16 U.S. Patent and Trademark Office (USPTO). That includes future potential pipeline candidates for indications including atopic dermatitis.On top of this, Azitra announced three newly allowed patents in the U.S., Canada, and China. The U.S. pate ...

Clinical Trials and Development Progress - ATR-12 Phase 1b trial advanced with clinical sites activated and initial Netherton syndrome patients identified for dosing, with primary endpoints focusing on safety and tolerability[2] - ATR-04 pre-IND meeting with FDA successfully completed, with IND submission planned for mid-2024 and Phase 1b trial initiation targeted for late 2024[2][3] - ATR-12 preclinical data presented at ASGCT shows superior LEKTI delivery and significant reduction of IL-36g, a pro-inflammatory cytokine implicated in Netherton syndrome[2][3] Financial and Funding Updates - Follow-on public offering completed in February 2024, raising $5.0 million in gross proceeds to support clinical programs[4] - Q1 2024 R&D expenses increased to $1.5 million compared to $0.8 million in Q1 2023[6] - Q1 2024 net loss was $2.9 million, compared to $2.5 million in Q1 2023[6] - Cash and cash equivalents as of March 31, 2024, totaled $3.0 million[6] Market Potential and Intellectual Property - ATR-12 estimated peak sales opportunity is ~$250 million, targeting a global prevalence of 20,000+ Netherton syndrome patients[4] - ATR-04 estimated peak sales opportunity exceeds $1 billion, targeting a U.S. prevalence of ~150,000 EGFRi-associated rash patients[5] - U.S. patent issued for treating skin diseases, including ichthyosis vulgaris, affecting approximately 1.3 million Americans[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | --- | |----------------- ...

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds. Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Completed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-41705 Azitra, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4478536 (State or Other Jurisdiction of I ...

Exhibit 99.1 Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates BRANFORD, Conn.—(BUSINESS WIRE)—Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights ● Completed an initial public offering, raising $7.5 million in gross proceeds. ● Obt ...